NCT07054970 - To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects | Biotech Hunter

Enrollment

172

Participants

Timeline

Start Date

January 12, 2024

Primary Completion Date

August 29, 2024

Study Completion Date

September 6, 2024

Conditions

Healthy Male Subjects

Interventions

BIOLOGICAL

CT-P55

150 mg in 1.0 mL, administered as a single SC injection via PFS

BIOLOGICAL

US-licensed Cosentyx

150 mg in 1.0 mL, administered as a single SC injection via PFS

BIOLOGICAL

EU-approved Cosentyx

150 mg in 1.0 mL, administered as a single SC injection via PFS

Trial Locations (4)

Yokohama Minoru Clinic, Yokohama

SOUSEIKAI Nishikumamoto Hospital, Kumamoto

Medical Corporation Heishinkai OPHAC Hospital, Osaka

Kitasato University Kitasato Institute Hospital, Minato-ku